A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery.
Bernadette JeremiasseRavian L van IneveldVeerle BokMichiel KleinnijenhuisSam de BlankMaria AlievaHannah R JohnsonEsmée J van VlietAmber L ZeemanLianne M WellensGerard Llibre-PalomarMario Barrera RománAlessia Di MaggioJohanna F DekkersSabrina OliveiraAlexander L VahrmeijerJan J MolenaarMarc Hwa WijnenAlida Fw van der SteegEllen J WehrensAnne C RiosPublished in: EMBO molecular medicine (2024)
Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.
Keyphrases
- fluorescence imaging
- single molecule
- high throughput
- photodynamic therapy
- minimally invasive
- small molecule
- living cells
- coronary artery bypass
- single cell
- case report
- high resolution
- endothelial cells
- poor prognosis
- surgical site infection
- energy transfer
- binding protein
- induced pluripotent stem cells
- mass spectrometry
- drug delivery
- dna binding
- cancer therapy
- quantum dots
- long non coding rna
- coronary artery disease